Page 354 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

328 Vanessa Quick and John Kirwan

[44] Unizony S, Stone JH, James R. New treatment strategies in large-vessel vasculitis.
Current Opinion in Rheumatology, 2013; 25:3-9.

[45] Hernandez-Rodriguez J et al. Elevated production of interleukin-6 is associated with a
lower incidence of disease-related ischemic events in patients with giant-cell arteritis:
angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation,
2003; 107:2428–2434.

[46] Smetana GW, Shmerling RH. Does the patient have temporal arteritis? JAMA, 2002;
287:92-101.

[47] Weyand CM and Goronzy JJ. Giant-Cell Arteritis and Polymyalgia Rheumatica. Ann.
Intern. Med., 2003; 139:505-515.

[48] Hunder GG. Clinical features of GCA/PMR. Clin. Exp. Rheumatol., 2000; 18(Suppl
20); S6-S8.

[49] Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis. A
pathological study to show the pattern of arterial involvement. Arch. Neurol., 1972;
27:378–391.

[50] Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic,
clinical, and pathologic study. Ann. Intern. Med., 1978; 88:162-167.

[51] Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: disease patterns
of clinical presentation in a series of 240 patients. Medicine 2005; 84:269-276.

[52] Ezeonyeji AN, Borg FA, Dasgupta B. Delays in recognition and management of giant
cell arteritis: results from a retrospective audit. Clin. Rheumatol., 2011; 30:259–262.

[53] Cooke WT, Cloake PCP, Govan ADT, et al. Temporal arteritis: A generalized vascular
disease. Q. J. Med., 1946; 15:47-75.

[54] Hunder GG. Diagnosis of giant cell (temporal) arteritis. In: UpToDate, Basow DS, ed.,
UpToDate:Waltham, MA, 2013, accessed 6/7/13.

[55] Mackie SL, Pease CT. Diagnosis and management of giant cell arteritis and
polymyalgia rheumatica: challenges, controversies and practical tips. Postgraduate
Medical Journal, 2013; 89:284-292.

[56] Calamia KT, Hunder GG. Giant cell arteritis (Temporal arteritis) presenting as fever of
undetermined origin. Arthritis Rheum., 1981; 24:1414-1418.

[57] Hayreh SS. Ophthalmic features of giant cell arteritis. Baillieres Clin.
Rheumatol., 1991; 5:431-459.

[58] González-Gay MA, García-Porrúa C, Llorca J, et al. Visual manifestations of giant cell
arteritis. Trends and clinical spectrum in 161 patients. Medicine, 2000; 79:283–292.

[59] Salvarani C, Cimino L, Macchioni P et al. Risk factors for visual loss in an Italian
population-based cohort of patients with giant cell arteritis. Arthritis Rheum., 2005;
5:293–297.

[60] Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular
manifestations. Am. J. Ophthalmol., 1998; 125:521–526.

[61] Valesky EM, Wahle M, Vranes S, et al. Bitemporal scalp necrosis, a very rare
manifestation of giant cell arteritis. Zeitschrift Fur. Rheumatologie, 2012; 71:806-809.

[62] Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis.
Lancet, 2008; 372: 234-245.

[63] Garcia-Martinez A, Hernandez-Rodriguez J, Arguis P, et al. Development of Aortic
Aneurysm/Dilatation During the Follow up of Patients With Giant Cell Arteritis: A

Complimentary Contributor Copy